PyelonephritisPhase 2PROPANCT01628900
Prospective Study in the Emergency
A Phase 2 study testing care management arm N°1 vs arm N°2 and Care management in people with Pyelonephritis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The prevalence of acute pyelonephritis (PNA) is 60-75 000/year. They are traditionally classified as uncomplicated (60-65%) and complicated. If it is assumed that the uncomplicated PNA can be treated as outpatients with a cure rate of over 80%, the second group is very heterogeneous. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pyelonephritis
- What is being tested?
- care management arm N°1 vs arm N°2 and Care management
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 1 siteFrance
- Study dates
- May 2012to Jul 2013
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- man or woman
- age ≥ 18 years
- signed a written informed consent
- Social security coverage
- have all the necessary signs for a PNA diagnosis
- whose ranking to PNA-1, PNA or PNA-2-3 is possible
Show all 15Show fewer
- Fever ≥ 38.5 ° C
- Or the possibility of hypothermia in the single case of PNA-3
- Of a spontaneous pain of one or both sides
- Pain caused to the costovertebral angle
- And presence of leukocyturia GB/mm3 ≥ 10 with or without nitriturie
- Imaging examination at least abdominopelvic ultrasound (EAP) or CT, excluding any other possible diagnoses
- Any suspected nosocomial PNA, defined as any PNA appeared within 48 hours of discharge from a medical institution. The residential facilities for the frail elderly (retirement homes), and other institutions for the aged, not medicalized, are not affected by this limitation.
- All uptake within 24 hours of: ciprofloxacin, ofloxacin, levofloxacin, or ceftriaxone.
- Taking antibiotics considered less active in E. coli (amoxicillin ± clavulanate, trimethoprim) or ineffective in the pna (norfloxacin), before arriving at the hospital regardless of its duration, is not an exclusion criteria. The approach should remain similar to those of other patients, and possible exclusion imposed only if the initial bacteriuria is ≤ 103 CFU / ml.
Who cannot join
- Pregnant or lactating women because they are also mother-child care
- Patients refusing to provide reliable contact information, especially phone number
- In general, patients with significant cognitive impairment, no entourage, because adherence to guidelines, treatment and monitoring can be very random
- The PNA 3 emergency situation such as no time to start antibiotics ("antibiotic Emergency" = 30 to 60 minutes between arrival and administration of antibiotics) or reanimation can not be accepted, especially if a third person was required to sign the consent. The typical example is the patient with septic shock.
Trial locations and contacts
1 site in 1 country.
France1 site
Hôpital Ambroise Paré
Boulogne-Billancourt, Île-de-France Region, 92100
About this study
Official title: New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency
The prevalence of acute pyelonephritis (PNA) is 60-75 000/year. They are traditionally classified as uncomplicated (60-65%) and complicated. If it is assumed that the uncomplicated PNA can be treated as outpatients with a cure rate of over 80%, the second group is very heterogeneous. Some patients are severely infected. But others, despite an older age, structural urologic abnormalities or a controlled history, have no risk factors and can be simply managed. The investigators propose to reclassify the PNA into 3 categories: uncomplicated PNA (PNA-1), the PNA of moderate severity (PNA-2), the major PNA (PNA-3) to test whether the PNA-2 can benefit from the same outpatient care that the PNA-1. The existence of biological markers of the severity of bacterial infections would further support a tailored approach. The pro-adrenomedullin (pro-ADM), successfully tested to identify severe community acquired pneumonia, is a an interesting candidate.
Read the detailed description
In Europe and North America, urinary tract infections (UTI) are the 2nd largest community-acquired infections. In the U.S., the number of annual doctor's consultations for UTI is estimated at 8 million and that of women's APN to 250,000. In Britain, an estimated number of 62 of 1000 women consult for UTI annually. Extrapolated to France, these figures would be 5-6 million annual consultations and 60 to 75 000 APN.
APN is an infection associated with urinary and pelvic and / or the renal parenchyma, marked by fever ≥ 38.5 ° C, spontaneous pain flank, pain caused to the cost vertebral angle and a positive urine dipstick (BU). Conversely, pain and fever can be reduced and 30% of PNA is as cystitis, a history of PNA is then so evocative.
Without a precise technology to detect possible renal micro-abscesses, scars of any APN, direct evidence of upper tract infection is rarely made. Positive blood cultures (30-50%of cases) are indirect evidence. In most cases, only infection of urine is affirmed by cyto-bacteriological examination (urinalysis), which results are available 48-72 hours after culturing. It is assumed that urine culture is positive when leukocyte's count is ≥ 104 cells per milliliter (GB / ml) and bacteriuria ≥ 105 colony forming unit (CFU) / ml of urine (maximum two) uropathogen germ. Therefore, diagnosis and treatment of PNA are probabilistic in the beginning, hence the interest of the BU. It is considered positive when the leukocyte count is ≥ 10 ± GB/mm3 with ± nitriturie. Done correctly, it has a positive predictive value (PPV) of 74% and NPV of 98%.
Classically there are two types of PNA, the complicated PNA and the non-complicated PNA, opposed by age, sex, severity, causative organisms and their sensitivity to antibiotics.
Uncomplicated PNA is the best defined. It occurs on a normal urinary tract in nonpregnant women, aged 15 to 65, with no systemic disease or urological surgery. It is not accompanied with by septic shock or renal abscesses. It is due to E. Coli in 90% of cases, sometimes to Klebsiella and Proteus sp, all susceptible to recommended antibiotics.
Its overall cure rate, defined as bacterial eradication and disappearance of signs and symptoms, observed in three visits over 6 weeks follow-up, is ≥ 80% treated at home or in hospital.
Other PNA, traditionally described as complicated, are not very well defined. It includes the PNA with septic shock, abscess or renal failure, the PNA in old women or in men. It also ranks the PNA occurring in urinary tract malformations, whether or not it has an impact in renal function (bifid pelvis or ureter, renal cyst). In all cases, the evolution is assumed less simple than that of PNA of young women without being unavoidably complicated. But there is no tool to measure the impact of chronic conditions on a PNA which degree of infection is not very severe.
A better understanding of the evolutionary potential of these various categories of PNA would adapt the therapeutic management. Different parameters would help this approach including the duration of antibiotic therapy, the place of care (home or hospital) and in this case, the optimal duration of hospitalization. It is recognized that the uncomplicated PNA in young women can be treated immediately at home by a single oral antibiotic for 7 days. For other categories of PNA, there generally recommend hospitalization to evaluate the effect of antibiotic therapy, which should not be less than two weeks. The benefit of this therapeutic approach is unknown.
Instead of the traditional terminology "complicated" and "uncomplicated" the investigators propose a new classification into three categories:
- non-severe or mild PNA, corresponding to the uncomplicated PNA (PNA-1)
- PNA of moderate severity, including less intense infectious syndrome which occurs on a chronic, stable and controlled disease,
- PNA with severe sepsis, septic shock or hemodynamic instability and / or immediately complicated by the fact of the presence of altered and / or progressive chronic disease with risk to decompensate (PNA-3).
In a prospective observational study in 34 French emergency services, 211 patients meeting PNA criteria were included in two weeks. They were divided into 62.5% of PNA-1, 24.6% of PNA-2 and 12.7% of PNA-3. This classification reflects the initial severity of the infection and the subsequent evolutionary potential, can distinguish a class 2. This differs from the other two by the lack of severity of the infection which it shares with the class 1 and by the existence of factors such as age or male, stable disease or abnormalities structural urological without systemic impact. The evolutionary potential risk associated with these factors, independent of the ITU, has never been measured.
The question is whether patients with a PNA-2 should be treated as a benign PNA or PNA with risk of further complications. The Infectious Diseases Society of America offers two treatment possibilities for these patients, and whose effectiveness has never been compared:
- Treatment at home with oral monotherapy, preferably a fluoroquinolone (FQ) for 7 days, as for a PNA-1,
- Or starting parenteral antibiotics followed by 12 to 24 hours of observation in short-term hospitalization unit (UHCD) before deciding if: return to home or prolong hospitalization.
Our hypothesis is that the prognosis of ANP is mainly related to the severity of initial infection and very secondarily to history or related conditions as they are controllable and little or no decompensated. In fact, the table being mild infection in the NAP-1 and NAP-2, they differ only by demographic factors (age, sex) or a history little influence on evolution. These two categories of PNA should logically receive the same support. To support this hypothesis, the investigators propose a controlled intervention trial in which the PNA-2 will be randomized between two treatment strategies, one of which corresponds to the management of PNA-1, to demonstrate their prognostic similarity.
In addition to this a priori classification, clinical data of the study will be used to construct a prognostic score. To this end, the investigators intend to measure the pro-adrenomedullin (pro-ADM) to all patients. Adrenomedullin, a powerful natural vasodilator,has also immunomodulatory and bactericidal properties which explain the increase OF ADM serum levels in severe systemic infections. However, the dosage is difficult because of its short half-life in blood. One of its degradation products, the pro-ADM, reflecting active ADM, is more stable and easily measurable. The dosage of pro-ADM has recently allowed the reliable assessment of individual prognosis of septic patients, particularly in the context of community-acquired pneumonia, the leading cause of death from infection. Although the pro-ADM is mainly used to predict the prognosis and that death is a rare complication of PNA community, the investigators will test its ability to distinguish between hospitalized PNA patients and outpatient. pro-ADM will be tested to improve the performance of the prognostic score.
- Conditions
- Pyelonephritis
- Being tested
- care management arm N°1 vs arm N°2, Care management
- Keywords
- pyelonephritis, Infection, Antibiotic treatment
- Medical subject headings
- Pyelonephritis, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
care management arm N°1 vs arm N°2Other
7 days for mono-antibiotherapy at hospital
Care managementOther
Hospital vs home
| Study group | Role | What they receive |
|---|---|---|
| ambulatory | Active comparator | Patient will be treated for 7 days at home, then 3 follow-up visit at hospital. Receives: Other: care management arm N°1 vs arm N°2; Other: Care management |
| hospitalisation | Active comparator | 7 days for mono-antibiotherapy at hospital. Receives: Other: care management arm N°1 vs arm N°2; Other: Care management |
What is being measured
The primary outcome is the main question the study is designed to answer.
The overall cure rate.
This is the clinical and bacteriological cure, defined by apyrexia, the disappearance of pain and bacteriuria <103 CFU / ml at the 3 follow-up consultations till 45 ± 3 days after the first day of inclusion (day 0), 6 weeks tracking in total.
Measured: 50 months
Secondary outcomes (3)
1) Evaluation in the two arms of the PNA-2 and PNA-1 classes
Evaluation in the two arms of the PNA-2 and PNA-1 classes:
- The rate of complications related to the strategy, including aggravation of infection and initial misdiagnosis
- Changes and duration of antibiotic therapy
- The rate of secondary hospitalizations
- The recovery time of the previous activity
- Rates of pro-ADM
Measured: 50 months
2) Evaluation in the PNA-3 category
In the PNA-3 category: duration of antibiotic therapy and hospitalization.
Measured: 50 months
3)For the three categories
For the three categories: evidence of association between clinical symptoms, history, age and sex, the rate of pro-ADM and healing to construct a prognostic score.
Measured: 50 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2012 (estimated)
- Study startMay 2012
- Primary completionApr 2013
- Study completionJul 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PyelonephritisStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David Elkharrat, MD, Principal investigator, Hospital Ambroise Paré Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01628900
- Sponsor's protocol ID
- AOM 10103
- Acronym
- PROPA
- Status last verified
- Jun 2011
- First submitted
- 14 May 2012
- Last updated
- 8 Oct 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency
- ClinicalTrials.gov ID
- NCT01628900
- Acronym / sponsor ID
- PROPA / AOM 10103
- Conditions
- Pyelonephritis
- Keywords
- pyelonephritis, Infection, Antibiotic treatment
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- May 2012
- Primary completion
- Apr 2013 (actual)
- Study completion
- Jul 2013 (actual)
- First posted
- 27 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of acute pyelonephritis (PNA) is 60-75 000/year. They are traditionally classified as uncomplicated (60-65%) and complicated. If it is assumed that the uncomplicated PNA can be treated as outpatients with a cure rate of over 80%, the second group is very heterogeneous. Some patients are severely infected. But others, despite an older age, structural urologic abnormalities or a controlled history, have no risk factors and can be simply managed. The investigators propose to reclassify the PNA into 3 categories: uncomplicated PNA (PNA-1), the PNA of moderate severity (PNA-2), the major PNA (PNA-3) to test whether the PNA-2 can benefit from the same outpatient care that the PNA-1. The existence of biological markers of the severity of bacterial infections would further support a tailored approach. The pro-adrenomedullin (pro-ADM), successfully tested to identify severe community acquired pneumonia, is a an interesting candidate.
Detailed description
In Europe and North America, urinary tract infections (UTI) are the 2nd largest community-acquired infections. In the U.S., the number of annual doctor's consultations for UTI is estimated at 8 million and that of women's APN to 250,000. In Britain, an estimated number of 62 of 1000 women consult for UTI annually. Extrapolated to France, these figures would be 5-6 million annual consultations and 60 to 75 000 APN.
APN is an infection associated with urinary and pelvic and / or the renal parenchyma, marked by fever ≥ 38.5 ° C, spontaneous pain flank, pain caused to the cost vertebral angle and a positive urine dipstick (BU). Conversely, pain and fever can be reduced and 30% of PNA is as cystitis, a history of PNA is then so evocative.
Without a precise technology to detect possible renal micro-abscesses, scars of any APN, direct evidence of upper tract infection is rarely made. Positive blood cultures (30-50%of cases) are indirect evidence. In most cases, only infection of urine is affirmed by cyto-bacteriological examination (urinalysis), which results are available 48-72 hours after culturing. It is assumed that urine culture is positive when leukocyte's count is ≥ 104 cells per milliliter (GB / ml) and bacteriuria ≥ 105 colony forming unit (CFU) / ml of urine (maximum two) uropathogen germ. Therefore, diagnosis and treatment of PNA are probabilistic in the beginning, hence the interest of the BU. It is considered positive when the leukocyte count is ≥ 10 ± GB/mm3 with ± nitriturie. Done correctly, it has a positive predictive value (PPV) of 74% and NPV of 98%.
Classically there are two types of PNA, the complicated PNA and the non-complicated PNA, opposed by age, sex, severity, causative organisms and their sensitivity to antibiotics.
Uncomplicated PNA is the best defined. It occurs on a normal urinary tract in nonpregnant women, aged 15 to 65, with no systemic disease or urological surgery. It is not accompanied with by septic shock or renal abscesses. It is due to E. Coli in 90% of cases, sometimes to Klebsiella and Proteus sp, all susceptible to recommended antibiotics.
Its overall cure rate, defined as bacterial eradication and disappearance of signs and symptoms, observed in three visits over 6 weeks follow-up, is ≥ 80% treated at home or in hospital.
Other PNA, traditionally described as complicated, are not very well defined. It includes the PNA with septic shock, abscess or renal failure, the PNA in old women or in men. It also ranks the PNA occurring in urinary tract malformations, whether or not it has an impact in renal function (bifid pelvis or ureter, renal cyst). In all cases, the evolution is assumed less simple than that of PNA of young women without being unavoidably complicated. But there is no tool to measure the impact of chronic conditions on a PNA which degree of infection is not very severe.
A better understanding of the evolutionary potential of these various categories of PNA would adapt the therapeutic management. Different parameters would help this approach including the duration of antibiotic therapy, the place of care (home or hospital) and in this case, the optimal duration of hospitalization. It is recognized that the uncomplicated PNA in young women can be treated immediately at home by a single oral antibiotic for 7 days. For other categories of PNA, there generally recommend hospitalization to evaluate the effect of antibiotic therapy, which should not be less than two weeks. The benefit of this therapeutic approach is unknown.
Instead of the traditional terminology "complicated" and "uncomplicated" the investigators propose a new classification into three categories:
- non-severe or mild PNA, corresponding to the uncomplicated PNA (PNA-1)
- PNA of moderate severity, including less intense infectious syndrome which occurs on a chronic, stable and controlled disease,
- PNA with severe sepsis, septic shock or hemodynamic instability and / or immediately complicated by the fact of the presence of altered and / or progressive chronic disease with risk to decompensate (PNA-3).
In a prospective observational study in 34 French emergency services, 211 patients meeting PNA criteria were included in two weeks. They were divided into 62.5% of PNA-1, 24.6% of PNA-2 and 12.7% of PNA-3. This classification reflects the initial severity of the infection and the subsequent evolutionary potential, can distinguish a class 2. This differs from the other two by the lack of severity of the infection which it shares with the class 1 and by the existence of factors such as age or male, stable disease or abnormalities structural urological without systemic impact. The evolutionary potential risk associated with these factors, independent of the ITU, has never been measured.
The question is whether patients with a PNA-2 should be treated as a benign PNA or PNA with risk of further complications. The Infectious Diseases Society of America offers two treatment possibilities for these patients, and whose effectiveness has never been compared:
- Treatment at home with oral monotherapy, preferably a fluoroquinolone (FQ) for 7 days, as for a PNA-1,
- Or starting parenteral antibiotics followed by 12 to 24 hours of observation in short-term hospitalization unit (UHCD) before deciding if: return to home or prolong hospitalization.
Our hypothesis is that the prognosis of ANP is mainly related to the severity of initial infection and very secondarily to history or related conditions as they are controllable and little or no decompensated. In fact, the table being mild infection in the NAP-1 and NAP-2, they differ only by demographic factors (age, sex) or a history little influence on evolution. These two categories of PNA should logically receive the same support. To support this hypothesis, the investigators propose a controlled intervention trial in which the PNA-2 will be randomized between two treatment strategies, one of which corresponds to the management of PNA-1, to demonstrate their prognostic similarity.
In addition to this a priori classification, clinical data of the study will be used to construct a prognostic score. To this end, the investigators intend to measure the pro-adrenomedullin (pro-ADM) to all patients. Adrenomedullin, a powerful natural vasodilator,has also immunomodulatory and bactericidal properties which explain the increase OF ADM serum levels in severe systemic infections. However, the dosage is difficult because of its short half-life in blood. One of its degradation products, the pro-ADM, reflecting active ADM, is more stable and easily measurable. The dosage of pro-ADM has recently allowed the reliable assessment of individual prognosis of septic patients, particularly in the context of community-acquired pneumonia, the leading cause of death from infection. Although the pro-ADM is mainly used to predict the prognosis and that death is a rare complication of PNA community, the investigators will test its ability to distinguish between hospitalized PNA patients and outpatient. pro-ADM will be tested to improve the performance of the prognostic score.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ambulatory | Active comparator | Other: care management arm N°1 vs arm N°2, Other: Care managementPatient will be treated for 7 days at home, then 3 follow-up visit at hospital. |
| hospitalisation | Active comparator | Other: care management arm N°1 vs arm N°2, Other: Care management7 days for mono-antibiotherapy at hospital. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- man or woman
- age ≥ 18 years
- signed a written informed consent
- Social security coverage
- have all the necessary signs for a PNA diagnosis
Key exclusion criteria (4 listed)
- Pregnant or lactating women because they are also mother-child care
- Patients refusing to provide reliable contact information, especially phone number
- In general, patients with significant cognitive impairment, no entourage, because adherence to guidelines, treatment and monitoring can be very random
- The PNA 3 emergency situation such as no time to start antibiotics ("antibiotic Emergency" = 30 to 60 minutes between arrival and administration of antibiotics) or reanimation can not be accepted, especially if a third person was required to sign the consent. The typical example is the patient with septic shock.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| care management arm N°1 vs arm N°27 days for mono-antibiotherapy at hospital | Other | ambulatory, hospitalisation |
| Care managementHospital vs home | Other | ambulatory, hospitalisation |
Primary outcome
The overall cure rate.
Time frame: 50 months
This is the clinical and bacteriological cure, defined by apyrexia, the disappearance of pain and bacteriuria <103 CFU / ml at the 3 follow-up consultations till 45 ± 3 days after the first day of inclusion (day 0), 6 weeks tracking in total.
3 secondary outcomes
1) Evaluation in the two arms of the PNA-2 and PNA-1 classes
Time frame: 50 months
2) Evaluation in the PNA-3 category
Time frame: 50 months
3)For the three categories
Time frame: 50 months
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2013.
Related trials for Pyelonephritis
Not yet recruitingPhase 2
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
Not yet recruitingObservational study
Real-World Study of Obstructive Upper Urinary Tract Stones and Acute Pyelonephritis
Urolithiasis, Strategy Training
Active, not recruitingPhase 2
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Acute Pyelonephritis, Complicated Urinary Tract Infection
RecruitingObservational study
Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study
Intra Abdominal Infections, Appendicitis Acute
RecruitingPhase 4
3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children
Pyelonephritis Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Elkharrat, MD principal investigator
Hospital Ambroise Paré Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing care management arm N°1 vs arm N°2 and Care management in people with Pyelonephritis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 8 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The overall cure rate. (time frame: 50 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2013.